Lemaitre Vascular (LMAT) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
219.9M
Gross Profit
150.9M
68.63%
Operating Income
52.3M
23.77%
Net Income
44.0M
20.03%
EPS (Diluted)
$1.93
Balance Sheet Metrics
Total Assets
551.8M
Total Liabilities
214.5M
Shareholders Equity
337.3M
Debt to Equity
0.64
Cash Flow Metrics
Operating Cash Flow
42.2M
Free Cash Flow
37.2M
Revenue & Profitability Trend
Lemaitre Vascular Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 219.9M | 193.5M | 161.7M | 154.4M | 129.4M |
| Cost of Goods Sold | 69.0M | 66.4M | 56.8M | 53.0M | 44.7M |
| Gross Profit | 150.9M | 127.0M | 104.9M | 101.4M | 84.6M |
| Operating Expenses | 98.6M | 89.9M | 75.0M | 65.0M | 56.3M |
| Operating Income | 52.3M | 37.2M | 29.9M | 36.4M | 28.3M |
| Pre-tax Income | 56.9M | 39.5M | 27.5M | 34.3M | 27.4M |
| Income Tax | 12.8M | 9.4M | 6.9M | 7.4M | 6.1M |
| Net Income | 44.0M | 30.1M | 20.6M | 26.9M | 21.2M |
| EPS (Diluted) | $1.93 | $1.34 | $0.93 | $1.25 | $1.04 |
Income Statement Trend
Lemaitre Vascular Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 402.2M | 194.6M | 161.7M | 139.9M | 94.3M |
| Non-Current Assets | 149.6M | 152.2M | 148.7M | 152.9M | 158.5M |
| Total Assets | 551.8M | 346.8M | 310.5M | 292.8M | 252.8M |
| Liabilities | |||||
| Current Liabilities | 30.6M | 29.9M | 25.3M | 21.8M | 25.1M |
| Non-Current Liabilities | 183.9M | 19.0M | 16.9M | 16.8M | 55.1M |
| Total Liabilities | 214.5M | 48.9M | 42.3M | 38.7M | 80.2M |
| Equity | |||||
| Total Shareholders Equity | 337.3M | 297.9M | 268.2M | 254.2M | 172.6M |
Balance Sheet Composition
Lemaitre Vascular Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 44.0M | 30.1M | 20.6M | 26.9M | 21.2M |
| Operating Cash Flow | 42.2M | 37.3M | 23.6M | 32.8M | 33.3M |
| Investing Activities | |||||
| Capital Expenditures | -7.0M | -7.3M | -2.4M | -4.9M | -959.0K |
| Investing Cash Flow | -200.1M | -24.7M | -10.4M | -61.1M | -52.9M |
| Financing Activities | |||||
| Dividends Paid | -14.4M | -12.4M | -11.0M | -9.3M | -7.7M |
| Financing Cash Flow | 159.8M | -6.3M | -9.2M | 13.7M | 7.2M |
| Free Cash Flow | 37.2M | 29.5M | 22.1M | 30.2M | 31.8M |
Cash Flow Trend
Lemaitre Vascular Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
42.77
Forward P/E
38.83
Price to Book
5.48
Price to Sales
8.41
PEG Ratio
38.83
Profitability Ratios
Profit Margin
19.96%
Operating Margin
21.09%
Return on Equity
13.77%
Return on Assets
7.28%
Financial Health
Current Ratio
16.49
Debt to Equity
53.33
Beta
0.82
Per Share Data
EPS (TTM)
$1.97
Book Value per Share
$15.38
Revenue per Share
$10.05
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| lmat | 1.9B | 42.77 | 5.48 | 13.77% | 19.96% | 53.33 |
| Intuitive Surgical | 189.7B | 77.39 | 11.09 | 15.96% | 28.41% | 0.00 |
| Becton, Dickinson | 50.0B | 33.87 | 1.98 | 5.89% | 7.18% | 76.34 |
| AtriCure | 1.6B | - | 3.46 | -8.38% | -7.95% | 17.03 |
| Azenta | 1.5B | -10.80 | 0.90 | -8.58% | -9.77% | 3.16 |
| Pulse Biosciences | 1.1B | -18.29 | 9.24 | -77.86% | 0.00% | 7.24 |
Financial data is updated regularly. All figures are in the company's reporting currency.